Molecular analysis of contiguous exons of the phenylalanine hydroxylase gene: identification of a new PKU mutation

I Dianzani, C Camaschella, G Saglio, G B Ferrero, S Ramus, A Ponzone, R G H Cotton

Abstract
A modified application of the chemical cleavage of mismatch (CCM) method has been used to screen three contiguous exons (exons 9, 10, and 11) of the phenylalanine hydroxylase gene in 17 Italian PKU patients. A new nonsense heterozygous C-G transversion within exon 11 (S359X) was identified in a single patient. Only one of the four mutations previously reported in this DNA region in Caucasians was found. This lesion, IVS X-546, was detected in five of the 34 PKU alleles examined. Our results underline the versatility of the CCM method for scanning a gene for multiple mutations. (J Med Genet 1993;30:228-31)

Phenylketonuria (PKU) is an inborn error of metabolism owing to deficiency of the liver enzyme phenylalanine hydroxylase (PAH). In the case of large genes with tissue specific expression like PAH, the unavailability of the correct tissue is a drawback to rapid identification of the causal mutations.2 Usually, single exons have to be screened for mutations. A number of methods for mutation detection have recently been proposed as an alternative to extensive sequencing. The most efficient methods are those able to screen both known and new mutations, such as denaturing gradient gel electrophoresis (DGGE),3 chemical cleavage of mismatch (CCM),4 and single strand conformation polymorphism (SSCP).5 All these methods eventually require sequence analysis for identification of the exact DNA change.

The possibility of studying multiple exons in the same assay speeds up the screening, as shown by the use of multiplex PCR analysis.6

We have recently used CCM to analyse simultaneously two contiguous exons (exons 7 and 8) of phenylalanine hydroxylase (PAH),7 taking advantage of the ability of CCM to screen large DNA fragments. We report here the screening of three other exons (9, 10, and 11) of the PAH gene from Italian PKU patients. A new mutation was identified in a single patient and a recently reported mutation, specific to Mediterranean PKU,89 was observed in several patients.

Materials and methods

Patients
Seventeen unrelated Italian PKU patients were investigated. The patients originated from different regions in Italy and were thus a representative section of the whole Italian population. RFLP haplotype determination was available for nine patients.10 Genomic DNA from patients and normal controls was extracted from peripheral blood leukocytes by standard techniques.

PCR amplification of PAH exons
Exons 9 and 10 of the PAH gene were amplified in a single polymerase chain reaction (PCR) using appropriate primers corresponding to the intron-exon boundaries, namely of intron 8-exon 9 (primer a, 5'-TATTTTCCCTATCAAGGAA-3') and of exon 10-intron 10 (primer b, 5'-AGGTGTACCTGTATA-TTCA-3'),11 as shown in fig 1. The length of the PCR product was approximately 2.5 kb (unavailability of the complete sequence of intron 9 allowed only an approximate estimate; for the same reason PCR primers were designed at intron-exon boundaries).

Exons 10 and 11 were amplified using a 5' primer (primer c, 5'-ATTGACTTTCATCCGATCCGG-3') complementary to the intron 9-exon 10 boundary and a 3' primer (primer d, 5'-ACCACCTACACCTTATCTTCT-3') complementary to the exon 11-intron 11 boundary.11 Since the length of intron 10 is 556 bp,99 the PCR product was 807 bp (fig 1).

PCR was performed using the Cetus Perkin Elmer PCR protocol using the following conditions: denaturation (105 seconds at 95°C), annealing (120 seconds at 65°C), and extension (180 seconds at 72°C) for 35 cycles. In both reactions the final MgCl2 concentration was 2.5 mmol/l.

The study of overlapping genomic fragments allowed us to screen all intron-exon boundaries.
Molecular analysis of contiguous exons of the phenylalanine hydroxylase gene: identification of a new PKU mutation

from represents 0, hydroxylamine; in sequence are generated hydroxylamine; bp

CCM ANALYSIS

Two different sets of experiments were performed: the first (experiment A) using PCR products encompassing exons 9–10 and the second (experiment B) using PCR products encompassing exons 10–11.

For each experiment, a uniformly labelled probe was obtained using DNA from a normal control. Probe labelling, purification of the labelled PCR product, heteroduplex production, and CCM reactions were performed as previously reported. The screening of overlapping DNA fragments increases the information obtained by using a uniformly labelled probe. Comparison of the two experiments allows localisation of mismatches within one of the two ends of the molecule in each reaction. Consequently, sequencing is reduced. The small regions corresponding to primers b and c at the boundaries of exon 10 are not included in the overlap, as mutations at primer sites are not detected.

ASO AND SEQUENCE ANALYSIS

Amplified PCR products were directly sequenced using the Sequenase DNA sequencing kit (United States Biochemical Corporation) and a protocol reported previously. ASO analysis was performed using oligonucleotides complementary to the mutated sequences of the two identified mutations. Amplified DNA from 130 PKU Italian alleles were used to identify the frequency of both mutations within the Italian population.

Results

CCM AND SEQUENCE ANALYSIS

Experiment A did not show mismatches within exons 9 and 10 of PAH from the PKU subjects, whereas experiment B showed two specific patterns of mismatches. The first was observed in a single patient and included three bands, mapping approximately at 140, 80, and 55 bp (fig 2A). Sequence analysis identified a C→G transversion mapping at position 134 of the PCR fragment (fig 2B). This mutation changes the TCA codon for serine 359 into a stop codon within exon 11 (S359X). We did not find any change corresponding to mismatches at 80 and 55 bp in the DNA from this patient.

However, sequence analysis of the control DNA used as a probe identified a recently reported G→C polymorphism at base 1377 (along with the normal sequence), corresponding to codon 385 and not to codon 430 as was previously reported (S Forrest, personal communication).

The presence of this polymorphism in the control DNA and of the mutation at codon 359 in the PKU patient, both changes in heterozygosity with the normal sequence, account for the three mismatches identified in the CCM reaction. In fact, three of all the possible heteroduplexes generated in this reaction are expected to react with hydroxylamine. One of them detects only the S359X mutation as a band at 134 bp, another only the codon 385 polymorphism as a band at 55 bp, whereas the third detects both changes and generates bands at 55 and 80 bp.

The second pattern of mismatch was represented by fragments at 184 and at 155 bp (fig 2C) and was seen in four patients. Since no mismatch was identified in the same patients when exons 9–10 were investigated, we assumed that the corresponding DNA changes were located close to exon 11 (exon 11 is 134 bp long). Since one out of the four patients showing the mismatch at 155 bp was homozygous for haplotype 6, we assumed that the 155 bp mismatch represented the CCM pattern of a common Mediterranean PKU mutation mapping 11 nucleotides before exon 11 and in linkage disequilibrium with haplotype 6 (IVS X-546, G→A). This hypothesis was confirmed by hybridisation of the DNA from all the 17 PKU patients with an ASO complementary to the IVS X-546 mutation (see below).

In all the four subjects the IVS X-546 mutation seems to be linked with a 184 bp mismatch. Since this mismatch was found in two PKU patients in which both PKU mutations had been completely characterised, the...
corresponding DNA change may be considered to be a harmless linked polymorphism.

ASA ANALYSIS

Hybridisation with an ASO complementary to the S359X mutation (5'-TACTGCTTA-TGAGAGAAGCC-3') on PCR products, obtained by using primers c and d and DNA from the 17 PKU patients, confirmed the data obtained by CCM analysis (fig 3B). ASA analysis of PCR products from the parents of the single patient carrier of S359X showed that the mutation was inherited from the mother (fig 3B). Twenty normal subjects similarly screened were proven not to carry the molecular lesion (data not shown).

Hybridisation with an ASO complementary to the IVS X-546 mutation on the same PCR products used above confirmed the data obtained by CCM analysis: only the four patients who showed the mismatch at 155 bp hybridised with the mutated ASO (fig 3A).

Analysis of 110 Italian PKU alleles by using ASOs complementary to both mutations allowed us to evaluate the frequency of these DNA changes within the Italian population: 0-8% for S359X and 10% for IVS X-546.

Discussion

Recent studies have suggested a different molecular basis for PKU in northern and southern Europe. The existence of a peculiar pattern of mutations in Italian PKU was first assumed on the basis of a different RFLP haplotype distribution and by the rarity of the two mutations that are most frequent in northern European PKU. Molecular heterogeneity was inferred both by haplotype distribution and by the association of different clinical phenotypes with the same haplotype.

Recently, this hypothesis has been confirmed by the identification of several mutations peculiar to Mediterranean populations and by the rarity of the many mutations identified in northern Europeans. However, the overall frequency of the seven mutations so far identified among Mediterraneans (IVS X-546, R261Q, R252W, P281L, IVS VII-1, R408W, IVS XII-1) still only accounts for approximately 40% of the Italian PKU alleles.

We were thus prompted to search for other causal mutations in Italian PKU. We focused our attention on the 3' region of the PAH gene because it encodes a portion of the protein essential for catalytic activity. In a previous study we screened a panel of Italian PKU patients for all the DNA changes which mapped within exons 7-8, the region which encodes the putative cofactor binding site for PAH. In this study we screened exons 9, 10, and 11.

A new mutation (S359X) was identified within exon 11 in a single PKU patient. Since it is a termination mutation, the mutated gene encodes for a truncated protein, lacking the region corresponding to exons 12 and 13 and most of exon 11. This region is essential for enzyme function, as shown by the absence of enzymatic activity of transformed cells containing another mutated PAH allele (IVS XII-1), which express a truncated protein lacking the C-terminus portion corresponding to exons 12 and 13. Thus, the S359X mutation is likely to be causal. Four causal mutations have been already reported to affect exons 9, 10, and 11 in Caucasians and were thus screened by our approach (L311P, IVS X-546, del364, S349R). Only one of these, IVS X-546, was found in our series. This mutation is in linkage disequilibrium with haplotype 6 in Mediterranean PKU patients. Its frequency calculated for 130 Italian PKU alleles (10%) corresponds to that reported for haplotype 6.

These findings further support the existence of molecular heterogeneity within Italian PKU. Such molecular heterogeneity might have originated through a founder effect within the multiple ethnic populations which represented Italy in the past.

Dr S M Forrest is thanked for criticism of the manuscript. We are greatly indebted to Dr S L C Woo for prepublication information regarding the IVS X-546 mutation. This work was partially supported by the National Australian Medical Research Foundation.

Molecular analysis of contiguous exons of the phenylalanine hydroxylase gene: identification of a new PKU mutation


I Dianzani, C Camaschella, G Saglio, G B Ferrero, S Ramus, A Ponzone and R G Cotton

*J Med Genet* 1993 30: 228-231
doi: 10.1136/jmg.30.3.228

Updated information and services can be found at:
http://jmg.bmj.com/content/30/3/228

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/